Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Prog Mol Biol Transl Sci. 2019;164:119-188. doi: 10.1016/bs.pmbts.2019.03.008. Epub 2019 Apr 11.
Despite recent advances in diagnosis and therapy having improved cancer outcome, many patients still do not respond to treatments, resulting in the progression or relapse of the disease, eventually impairing survival expectations. The limited efficacy of therapy is often attributable to its inability to affect cancer stem cells (CSCs), a small population of cells resistant to current radio- and chemo-therapies. CSCs are characterized by self-renewal and tumor-initiating capabilities, and function as a reservoir for the local and distant recurrence of the disease. Therefore, new therapeutic approaches able to effectively target and deplete CSCs are urgently needed. Immunotherapy is facing a renewed interest for its potential in cancer treatment, and the possibility of harnessing the immune system to target CSCs is being addressed by a new exciting research field. In this chapter, we discuss the cancer stem cell model and illustrate CSC biological and molecular properties, critically addressing theoretical and practical issues linked with their definition and study. We then review the existing literature regarding the immunological properties of CSCs and the complex interplay occurring between CSCs and immune cells. Finally, we present up-to-date studies on CSC immunotargeting and its potential future perspective. In conclusion, understanding the interplay between CSC biology and tumor immunology will provide a deeper understanding of the mechanisms that regulate CSC immunological properties. This will contribute to the design of new CSC-directed immunotherapeutic strategies with the potential of strongly improving cancer outcomes.
尽管近年来在诊断和治疗方面的进展提高了癌症的治疗效果,但许多患者仍然对治疗没有反应,导致疾病进展或复发,最终影响了生存预期。治疗的效果有限往往是因为它不能影响癌症干细胞(CSC),一小部分对当前的放射和化学疗法有抵抗力的细胞。CSC 的特征是自我更新和肿瘤起始能力,并作为疾病局部和远处复发的储备。因此,迫切需要新的治疗方法来有效地靶向和耗尽 CSC。免疫疗法因其在癌症治疗中的潜力而重新受到关注,利用免疫系统靶向 CSC 的可能性正在一个新的令人兴奋的研究领域中得到解决。在这一章中,我们讨论了癌症干细胞模型,并说明了 CSC 的生物学和分子特性,批判性地解决了与它们的定义和研究相关的理论和实践问题。然后,我们回顾了关于 CSC 免疫特性以及 CSC 和免疫细胞之间发生的复杂相互作用的现有文献。最后,我们介绍了最新的关于 CSC 免疫靶向的研究及其潜在的未来前景。总之,了解 CSC 生物学和肿瘤免疫学之间的相互作用将有助于深入了解调节 CSC 免疫特性的机制。这将有助于设计新的针对 CSC 的免疫治疗策略,有可能大大改善癌症的治疗效果。